What does a modified-Fibonacci dose-escalation actually correspond to?
What does a modified-Fibonacci dose-escalation actually correspond to?
复制标题
DOI：
10.1186/1471-2288-12-103
复制
发表时间：
2012-07-23
影响因子：
4
通讯作者：
Kramar, Andrew
中科院分区：
文献类型：
--
作者：
Penel, Nicolas;Kramar, Andrew
背景：在大多数I期肿瘤学试验中，通常认为剂量增量遵循“改良斐波那契序列”。这个词，然而，是vigil.Methods：为了更好地描述这个序列，我们回顾了81个I期试验基于这个概念。结果：出198个I期肿瘤学试验，81（41%）是基于修改后的斐波那契系列。实际的递增比率从0.80到2.08不等。实际增量的中位数约为2.00、1.50、1.33、1.33、1.33、1.30、1.35......。“修改后的斐波那契序列”收集真正的序列，这并不倾向于一个常数在较高的剂量levels.Conclusion：这个令人困惑的术语应避免异质性的变化。
Background: In most phase I oncology trials, it is often stated that the dose increments follow a "modified-Fibonacci sequence". This term, however, is vague.Methods: To better characterize this sequence, we reviewed 81 phase I trials based on this concept.Results: Out of 198 phase I oncology trials, 81 (41%) are based on modified-Fibonacci series. Actual incremental ratios varied in a large range from 0.80 to 2.08. The median of actual increments was about 2.00, 1.50, 1.33, 1.33, 1.33, 1.33, 1.30, 1.35.... The "modified Fibonacci-sequence" gathers heterogeneous variation of the genuine sequence, which does not tend to a constant number at higher dose-levels.Conclusion: This confusing term should be avoided.